Darmiyan's BrainSee nabs breakthrough status from FDA

2021 04 27 21 49 7389 Woman Dementia Alzheimer 400

The U.S. Food and Drug Administration (FDA) has granted breakthrough status to Darmiyan's artificial intelligence (AI)-based software, BrainSee, which detects Alzheimer's disease from MRI scans.

BrainSee detects Alzheimer's disease at the early stage of mild cognitive impairment using a brain MRI. The scan does not require an injection or radiation. The software will enable clinicians to select patients who are in the early stages of neurodegeneration for clinical trials, paving the way for potential new therapies and treatments.

Page 1 of 604
Next Page